(Q42675109)

English

Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

scientific article published on January 2006

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

based on heuristic

inferred from title

author name string

Claude Schulman

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Peter Pommerville

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Klaus Höfner

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Barton Wachs

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

73-9; discussion 79-80

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

The role of dihydrotestosterone in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05909.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2005.05909.X

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42675109&oldid=1965211364"